These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32992708)

  • 1. ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Oshi M; Newman S; Murthy V; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32992708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.
    Lin Y; Lin E; Li Y; Chen X; Chen M; Huang J; Guo W; Chen L; Wu L; Zhang X; Zhang W; Jin X; Zhang J; Fu F; Wang C
    Pathol Oncol Res; 2022; 28():1610559. PubMed ID: 36405394
    [No Abstract]   [Full Text] [Related]  

  • 4. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Herrero-Vicent C; Guerrero A; Gavilá J; Gozalbo F; Hernández A; Sandiego S; Algarra MA; Calatrava A; Guillem-Porta V; Ruiz-Simón A
    Ecancermedicalscience; 2017; 11():759. PubMed ID: 28900472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
    Tang X; Thompson KJ; Kalari KR; Sinnwell JP; Suman VJ; Vedell PT; McLaughlin SA; Northfelt DW; Aspitia AM; Gray RJ; Carter JM; Weinshilboum R; Wang L; Boughey JC; Goetz MP
    Breast Cancer Res; 2023 May; 25(1):57. PubMed ID: 37226243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
    Zhang L; Wang XI; Zhang S
    Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.
    Wang RX; Ji P; Gong Y; Shao ZM; Chen S
    Front Immunol; 2022; 13():940635. PubMed ID: 36341391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer.
    Fisher TB; Saini G; Rekha TS; Krishnamurthy J; Bhattarai S; Callagy G; Webber M; Janssen EAM; Kong J; Aneja R
    Breast Cancer Res; 2024 Jan; 26(1):12. PubMed ID: 38238771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Baez-Navarro X; van den Ende NS; Nguyen AH; Sinke R; Westenend P; van Brakel JB; Stobbe C; Westerga J; van Deurzen CHM
    Breast Cancer Res; 2024 Mar; 26(1):41. PubMed ID: 38468323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and Prognostic Value of Tumor- Infiltrating Lymphocytes for Pathological Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
    Mohammed AA; Mostafa Elsayed F; Algazar M; Rashed HE
    Gulf J Oncolog; 2022 Jan; 1(38):53-60. PubMed ID: 35156645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.